Viridian Therapeutics, Inc.\DE Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2013 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Viridian Therapeutics, Inc.\DE quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2013 to Q4 2024.
  • Viridian Therapeutics, Inc.\DE Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$79.7M, a 19.2% decline year-over-year.
  • Viridian Therapeutics, Inc.\DE Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$270M, a 13.6% decline year-over-year.
  • Viridian Therapeutics, Inc.\DE annual Net Income (Loss) Attributable to Parent for 2024 was -$270M, a 13.6% decline from 2023.
  • Viridian Therapeutics, Inc.\DE annual Net Income (Loss) Attributable to Parent for 2023 was -$238M, a 83.1% decline from 2022.
  • Viridian Therapeutics, Inc.\DE annual Net Income (Loss) Attributable to Parent for 2022 was -$130M, a 63.5% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$270M -$79.7M -$12.9M -19.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-03
Q3 2024 -$257M -$76.7M -$29M -60.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$228M -$65M -$9.93M -18% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$218M -$48.5M +$19.6M +28.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$238M -$66.9M -$21.1M -46% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-03
Q3 2023 -$217M -$47.7M -$18.8M -64.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$198M -$55.1M -$25.6M -86.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$172M -$68.2M -$42.5M -165% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$130M -$45.8M -$16.8M -58.2% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-03
Q3 2022 -$113M -$28.9M -$14.9M -106% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$98.2M -$29.5M -$11.5M -64.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$86.6M -$25.7M -$7.23M -39.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$79.4M -$28.9M +$61.8M +68.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$141M -$14M -$8.55M -156% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$133M -$18M -$11.5M -179% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$121M -$18.5M -$10.4M -129% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$111M -$90.7M -$80.6M -797% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 -$30.1M -$5.49M +$5.74M +51.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$35.8M -$6.44M +$2.46M +27.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-05
Q1 2020 -$38.3M -$8.04M +$3.59M +30.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-05
Q4 2019 -$41.9M -$10.1M +$199K +1.93% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-13
Q3 2019 -$42.1M -$11.2M -$2.22M -24.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$39.9M -$8.9M -$182K -2.09% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$39.7M -$11.6M -$6.97M -149% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$32.7M -$10.3M -$3.93M -61.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$28.8M -$9.01M -$3.18M -54.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-13
Q2 2018 -$25.6M -$8.71M -$1.4M -19.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-13
Q1 2018 -$24.2M -$4.66M +$2.32M +33.2% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-13
Q4 2017 -$26.5M -$6.39M -$412K -6.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$26.1M -$5.83M -$1.68M -40.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$24.4M -$7.31M -$3.79M -107% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$20.6M -$6.98M -$3.36M -92.7% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$17.3M -$5.97M -$2.99M -100% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$14.3M -$4.15M -$1M -31.8% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-15
Q2 2016 -$13.3M -$3.52M -$962K -37.5% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-15
Q1 2016 -$12.3M -$3.62M -$989K -37.5% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-15
Q4 2015 -$11.3M -$2.98M -$722K -32% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-24
Q3 2015 -$10.6M -$3.15M -$1.52M -92.5% Jul 1, 2015 Sep 30, 2015 10-Q 2016-10-26
Q2 2015 -$9.09M -$2.56M +$727K +22.1% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 -$9.82M -$2.63M -$1.93M -273% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
Q4 2014 -$7.89M -$2.26M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-21
Q3 2014 -$1.64M -$697K -74.2% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-13
Q2 2014 -$3.29M -$2.66M -422% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-14
Q1 2014 -$706K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15
Q3 2013 -$940K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-14
Q2 2013 -$630K Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.